Natera’s EDEN study on board

Introduction

Natera, Inc., a leading clinical genetic testing company aiming on technologies for better health and organs of women. Since 2003, the company has dedicated its operations to an intensified molecular diagnostics like Panorama, Prospera and Signatera. The company’s precision in the oncology sector for women brings progress in this extreme condition.

Announcement

Natera, Inc. excitedly introduced the EDEN study involving various keys to different prospective which qualifies assessing Natera’s non-invasive prenatal screening test for any complicated issues in pregnancy and in early risk evaluation of preeclampsia. Women’s health does have many spectrums of care and precision, but the consistent evaluation of studies and capturing new possibilities to ease their concerns is a first priority of Natera.

This new study is trying to cover all serious complication indications, ensuring awareness and depth of the cause in time. This will help decision-making for both professionals, patients, and their families. This study speaks volume of the company’s consistent efforts to prevent any adversity in women’s overall health and pregnancy.

EDEN Study specification

The EDEN study is one of the unified prenatal risk evaluation tests that involves merging of clinical data, extra analysis and cell-free DNA (cfDNA). This study aims to register around 7,500 pregnant women between 9 and 15 weeks of gestation in the United States. During these weeks, the assessment of the risk volume for preeclampsia, consisting of additional extreme disease and earlier onset disease, along with the negative pregnancy outcomes, will bring this study into action.

The company’s new test is a boost from the existing published research, which illustrated the connections between the negative results in pregnancy and cfDNA pointers. The study seems to hold a fundamental role and intention regarding the extreme preeclampsia that occurs in around 5-8% of pregnancy cases and becomes a permanent reason for neonatal and maternal morbidity. Learning the depth of these conditions approximates and sensitivity, the clinical guidelines suggest a lower dose of aspirin for individuals easily developing the risk for preeclampsia.

Senior vice president of medical affairs at Natera, Sheetal Parmar, said, “For years or company has upgraded pregnancy care to core via fragile and effective non-invasive testing. With this new study, we are assessing a future effective test. This test is engineered to address pregnancies where there are risk for any serious complications and preeclampsia before or with a super accuracy level. Following this, we use existing data of routine prenatal care.”